W-13 hydrochlorideCAS# 88519-57-7 |
- AL 8697
Catalog No.:BCC8037
CAS No.:1057394-06-5
- Skepinone-L
Catalog No.:BCC1953
CAS No.:1221485-83-1
- SB202190 (FHPI)
Catalog No.:BCC1093
CAS No.:152121-30-7
- BIRB 796 (Doramapimod)
Catalog No.:BCC2535
CAS No.:285983-48-4
- TAK-715
Catalog No.:BCC3968
CAS No.:303162-79-0
- SB 203580 hydrochloride
Catalog No.:BCC4293
CAS No.:869185-85-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 88519-57-7 | SDF | Download SDF |
PubChem ID | 16760706 | Appearance | Powder |
Formula | C14H18Cl2N2O2S | M.Wt | 349.27 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
Chemical Name | N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide;hydrochloride | ||
SMILES | C1=CC2=C(C=CC(=C2)S(=O)(=O)NCCCCN)C(=C1)Cl.Cl | ||
Standard InChIKey | QKAALLVQBOLELJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H17ClN2O2S.ClH/c15-14-5-3-4-11-10-12(6-7-13(11)14)20(18,19)17-9-2-1-8-16;/h3-7,10,17H,1-2,8-9,16H2;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Calmodulin antagonist (inhibits calmodulin activated PDE activity with an IC50 of 68 μM). Inhibits growth of tamoxifen-resistant breast cancer cells. |
W-13 hydrochloride Dilution Calculator
W-13 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8631 mL | 14.3156 mL | 28.6311 mL | 57.2623 mL | 71.5779 mL |
5 mM | 0.5726 mL | 2.8631 mL | 5.7262 mL | 11.4525 mL | 14.3156 mL |
10 mM | 0.2863 mL | 1.4316 mL | 2.8631 mL | 5.7262 mL | 7.1578 mL |
50 mM | 0.0573 mL | 0.2863 mL | 0.5726 mL | 1.1452 mL | 1.4316 mL |
100 mM | 0.0286 mL | 0.1432 mL | 0.2863 mL | 0.5726 mL | 0.7158 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rosamultin
Catalog No.:BCN7391
CAS No.:88515-58-6
- LY 2389575 hydrochloride
Catalog No.:BCC7985
CAS No.:885104-09-6
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
- Dichotomitin
Catalog No.:BCN8524
CAS No.:88509-91-5
- ARRY 520 trifluoroacetate
Catalog No.:BCC2391
CAS No.:885060-09-3
- ARRY-520 R enantiomer
Catalog No.:BCC1368
CAS No.:885060-08-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
- Farrerol 7-O-glucoside
Catalog No.:BCN6412
CAS No.:885044-12-2
- Manassantin A
Catalog No.:BCC8207
CAS No.:88497-87-4
- Artesunate
Catalog No.:BCN2457
CAS No.:88495-63-0
- Murraxocin
Catalog No.:BCN4431
CAS No.:88478-44-8
- (E)-FeCP-oxindole
Catalog No.:BCC6078
CAS No.:884338-18-5
- Kongensin A
Catalog No.:BCN4432
CAS No.:885315-96-8
- MK-8745
Catalog No.:BCC3994
CAS No.:885325-71-3
- HJC 0350
Catalog No.:BCC6302
CAS No.:885434-70-8
- Minumicrolin
Catalog No.:BCN4433
CAS No.:88546-96-7
- CCT128930
Catalog No.:BCC3904
CAS No.:885499-61-6
- 5'-O-Acetyljuglanin
Catalog No.:BCN6846
CAS No.:885697-82-5
- c-FMS inhibitor
Catalog No.:BCC1472
CAS No.:885704-21-2
- Fmoc-ε-Acp-OH
Catalog No.:BCC3206
CAS No.:88574-06-5
- Isomexoticin
Catalog No.:BCN4434
CAS No.:88585-86-8
- LY2119620
Catalog No.:BCC5564
CAS No.:886047-22-9
- Chrysin 7-O-beta-gentiobioside
Catalog No.:BCN2943
CAS No.:88640-89-5
- Cerebroside B
Catalog No.:BCN4435
CAS No.:88642-46-0
Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1).[Pubmed:9705360]
J Biol Chem. 1998 Aug 21;273(34):22145-50.
One of the major signaling pathways by which extracellular signals induce cell proliferation and differentiation involves the activation of extracellular signal-regulated kinases (ERKs). Because calmodulin is essential for quiescent cells to enter cell cycle, the role of calmodulin on ERK2 activation was studied in cultured fibroblasts. Serum, phorbol esters, or active Ras induced ERK2 activation in NIH 3T3 fibroblasts. This activation was not inhibited by calmodulin blockade. Surprisingly, inhibition of calmodulin prior to fetal bovine serum addition prolonged activation of ERK2. Furthermore, inactivation of calmodulin in serum-starved cells induced ERK2 phosphorylation that was dependent on MAP kinase kinase (MEK). Inactivation of calmodulin in serum-starved cells also induced activation of Ras, Raf, and MEK. On the contrary, tyrosine phosphorylation of tyrosine kinase receptors was not observed. These results indicate that calmodulin inhibits ERK2 activation pathway at the level of Ras. Calmodulin inhibition induced overexpression of p21(cip1) which was dependent on MEK activity. We propose that inhibition of Ras by calmodulin prevents the activation of ERK2 at low serum concentration. Thus, entering into the cell cycle after serum addition would imply the overcoming of the inhibitory effect of calmodulin and consequently ERK2 activation. Furthermore, down-regulation of Ras by calmodulin may be also important to determine the duration of ERK2 activation and to prevent a high p21(cip1) expression that would lead to an inhibition of cell proliferation.
Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.[Pubmed:1403784]
J Pharmacol Exp Ther. 1992 Oct;263(1):186-93.
Estrogen receptor (ER)-negative human breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and ER-positive derivatives of the MCF-7 cell line selected for growth in the presence of antiestrogens (LY2 and RR) were used as in vitro models of tamoxifen-resistant human breast cancer in this study. The sensitivity of the tamoxifen-sensitive (MCF-7) and tamoxifen-resistant human breast cancer cell growth to two noncytotoxic neuroleptic drugs, pimozide and thioridazine, and the anticalmodulin agent, W-13, were compared. Inhibition of cell growth was measured as a decrease in cell number following a 72-h incubation with drug. Growth of the ER-negative cell lines MDA-MB-231 and MDA-MB-435 was inhibited by all three drugs. The average Ki values in these two lines were 6.3 and 3.8 microM for pimozide and 4.1 and 15 microM for thioridazine, respectively. Both ER-negative cell lines were more sensitive than MCF-7 cells to growth inhibition by W-13. MCF-7 cells selected for antiestrogen resistance were sensitive to growth inhibition by W-13 and thioridazine (LY2, average Ki = 10.4 microM; RR, average Ki = 5.2 microM). LY2 and RR cells were resistant to pimozide except when treated with estradiol (Ki = 4.6 and 7.9 microM, respectively). Pimozide, thioridazine and W-13 all exerted different effects on the distribution of human breast cancer cells within the cell cycle, suggesting that each drug may utilize a distinct pathway for inhibition of cell growth. We conclude that all three drugs are potential noncytotoxic alternatives to tamoxifen for the treatment of tamoxifen-resistant human breast cancer.